Genprex, Inc. · NASDAQ:GNPX
Genprex — Investor Presentation (July 2021)
48 slides from Genprex's investor presentation, Jul 12, 2021
Slide 1: Reprogramming the Course of Cancer and Diabetes
©) Genprex REPROGRAMMING THE COURSE OF CANCER AND DIABETES NASDAQ: GNPX July 2021
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS Reform Act of the caption “se which they were mage company. mar ‘ ith al igs any kin whatsoever are granted othe rciplent. © Genprex Nassogsonex 2
Slide 3: GNPX at a Glance
GNPX AT A GLANCE jem | ome | | (is jst fat | | Genprex,inc. _ GNPX Nasdaq, 8.17 150m ak 47527857 $47.1 Million Genprex Naso: ex
Slide 4: Investment Highlights
INVESTMENT HIGHLIGHTS Novel gene therapies addressing cancer and diabetes 2 Jaf Genprexs nen-vral Oncoprex nanoparticle delivery system i designed to deliver eyo apa peesto hgh ull pes of oer nie ~ ‘canbe combined ‘wth top-sling cancer drugs and may improve their benef lang eaneee Working with world
Slide 5: Executive Summary
EXECUTIVE SUMMARY MAJOR COMPETITIVE ADVANTAGES GENE THERAPY PLATFORM DEMONSTRATED CLINICAL ACHIEVEMENT. FIRST SYSTEMIC GENE THERAPY INITIATING TWO LUNG CANCER TRIALS USED FOR CANCER IN HUMANS IN 2021 LARGE MARKETS AND UNMET NEED WORLD-CLASS ACADEMIC PARTNERS COMBINATION TRIALS WITH TOP SELLING CANCE
Slide 6: Research and Development Pipeline
RESEARCH AND DEVELOPMENT PIPELINE | <<? TT once SS ee © Genprex Nasdag:GNEK 6
Slide 7: Bridging Gaps in Modern Medicine
BRIDGING GAPS IN MODERN MEDICINE HELPING PATIENTS WITH LIMITED TREATMENT OPTIONS ONCOLOGY DIABETES ‘+ Genprex’s oncology combination treatment ‘© Gene therapy drug candidate addresses Type 1 and approach utilizes targeted therapies and Type 2 diabetes. immunotherapies. '* May reduce or eliminate dai
Slide 8: Oncology Program
ONCOLOGY PROGRAM
Slide 9: Non-Small Cell Lung Cancer
NON-SMALL CELL LUNG CANCER MARKET STATISTICS MOST COMMON LUNG CANCER TAGRISSO 2020 SALES NSCLC WORLDWIDE CASES KEYTRUDA 2020 SALES More than two million cases per year worldwide, Merck's highest grossing product. 6 a 3 B t UNITED STATES GLOBAL MARKET More than 200,000 new cases per year in the U.S.
Slide 10: Novel Platform to Treat Cancer
NOVEL PLATFORM TO TREAT CANCER ONCOPREX® NANOPARTICLE DELIVERY SYSTEM The first systemic gene therapy delivery platform for cancer GENES ‘SYNERGIES Multiple tumor Advanced approach suppressor genes using combination therapy CANCERS Multiple cancers Genprex Nasdog:GNeK 10
Slide 11: Oncoprex Nanoparticle Delivery System
ONCOPREX NANOPARTICLE DELIVERY SYSTEM CATIONIC LIPID NANOPARTICLE CARRIES DRUG TO TUMORS Cell death Our non-viral, biodegradable, positively-charged lipid is to negatively-charged cancer cells, with up to a 33-fold uptake in cancer cells vs, normal cells and has been well tolerated in humans with >
Slide 12: Targeting Negative Surface Charges of Cancer Cells
TARGETING NEGATIVE SURFACE CHARGES OF CANCER CELLS AN INNOVATIVE MEANS TO SELECTIVELY TARGET CANCER CELLS + The activities of glucose metabolism have a profound impact on the surface of cancer cells + Elevated glycolysis in cancer cells lead to a higher secretion of lactate + Secreted lactate ions r
Slide 13: REQORSA Targets Cancer at Its Core
REQORSA™ TARGETS CANCER AT ITS CORE DOTAP: CHOL-TUSC2 CONTROLS CELL SIGNALING STIMULATES APOPTOTIC PATHWAYS + MODULATES IMMUNE RESPONSE Pan-kinase inhibition Leads to death ity against proliferation ‘cancer Genprex Naséoa:GNex 13
Slide 14: TUSC2 Inhibits Key Cell Signaling
TUSC2 INHIBITS KEY CELL SIGNALING TUSC2 TUMOR SUPPRESSOR GENE HAS PAN-KINASE ACTIVITY THAT CAN OVERCOME CANCER RESISTANCE PATHWAYS Nasdaq: Nex 14
Slide 15: REQORSA Modulates the Immune System
REQORSA MODULATES THE IMMUNE SYSTEM A Active Teas ture) sregintungtetntan © axintung Meat is r i- i. : : 3 ve. ij * immunomodulation of Carbo + Pembro + « be TUSC2 demonstrates rationale for the on SE < So oe Acclaim-1 = Fe Seen ita peace nate So eee ee waumamae me Naséea:GNex 15
Slide 16: REQORSA Monotherapy
REQORSA MONOTHERAPY ONC-001 TRIAL DOSE ESCALATION STUDY Explore toxicity and tolerability in patients. Phase 1 monotherapy results: 31 Stage IV patients with at least 1 of 6 trial doses 23 patients evaluable Cancer growth halted in 5 of 23 patients Stable disease n=5; responses n=: Maximum Tolerated
Slide 17: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION PHASE 2 PRELIMINARY DATA IN SUBJECTS WITH OR WITHOUT EGFR MUTATIONS PATIENT EGFR STATUS RESPONSE a “INE ¢ Positive (exon 1820) Complete Response chemo 3 Negative Zey tegression Target lesion chemo/ant-PD1 2 30% regression one Target Les Negative TON repression al Toren
Slide 18: REQORSA + Tarceva Combination
REQORSA + TARCEVA COMBINATION ‘Swimmer Plot of Best Response, with Time on Study Negative sD Negative 4 so § Positive exon 18420) + © 3 3 Negative 4 sD z Neg TT SD 3 Negative 4 sD 3 eve | TT $2 & egtve | 3 Negative sD & sD 2 ‘# Chemotherapy — <= = = ‘4 Chemotherapy+immunotherapy Negative | SD tee so
Slide 19: AACR 21: REQORSA + Tagrisso Reduce Tumor Growth in Resistant Tumors
AACR 21: REQORSA + TAGRISSO REDUCE TUMOR GROWTH IN Genprex TAGRISSO-RESISTANT TUMORS 'H1975 tumors in NSG mice Osimertinib+TUSC2 combination on i i“ 180 — 1 * ont ramen oue ee OH 025 O28 O52 OM Ose OW Dit 025 Of O82 O56 Oe Days Days o cononsoun oe Conrat es) 3 Tuscz oer or, = rscz ie Gahran oun tomo
Slide 20: Acclaim-1 General Study Characteristics
ail Acclaim - 1 GENERAL STUDY ees lat rs uc Pe rh fer Tagrisso 715 US. sites Phase 1: 9-18 patients Phase 2:74 patients Inerim analysis at 51 events, dsase progression or death) Initiated Acciaim-1 clinical trial in June 20: STUDY ARM REQORSA + TAGRISSO g vs. First progression ‘Second progression =
Slide 21: Phase 1/2 Study Design and Endpoints
PHASE 2 FE Zz ry Zz i} i = fe} is) 3+3 dose escalation of REQORSA in combinat Tagrisso + Randomized 1:1, open-label, vs. Tagrisso monotherapy ya with PRIMARY ENDPOINT + Dose limiting toxicity PRIMARY ENDPOINT SECONDARY ENDPOINTS «Progression free survival (PFS) ‘Overall response rate + PFSimprovemen
Slide 22: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA IS SYNERGISTIC WITH ANTI-PD1 IN A SYNGENEIC MOUSE MODEL OF LUNG CANCER veant TUSC2+anti-PD1 combination significantly prolonged TUSC2+anti-PD1 exhibit greater antitumor activity than Al a fe recess cid refracton’ we either agent alone or control ‘ch
Slide 23: REQORSA Shows Synergy with Immunotherapies
REQORSA SHOWS SYNERGY WITH IMMUNOTHERAPIES REQORSA WITH ANTI-PD1 IN A MOUSE MODEL OF LUNG CANCER REQORSA + Keytruda REQORSA + Keytruda + Chemo Strong antitumor immune responses of anti-PD1 were REQORSAtanti-PD1+chemo combination resulted found against PDX tumors developed in humanized in metastasis
Slide 24: AACR 21: REQORSA May Enhance First-Line Standard of Care
AACR 21: REQORSA MAY ENHANCE FIRST-LINE STANDARD OF CARE REQORSA MAY OVERCOME RESISTANCE TO KEYTRUDA + CHEMO COMBINATION REQORSA + Keytruda + Chemo : Immunity in KRAS-LKB1 (KL)-mutant NSCLC in clinically relevant humanized mice models. “Tipe eatment on AS4S ung met in humanized mice Tumor Intensity
Slide 25: Acclaim-2 General Study Characteristics
GENERAL STUDY CHARACTERISTICS, Phase 1/2 study of Merck & Co's LC on track 021. i I feedback from KOLs, 1B members and trial design, + Targeting late-stage NSCLC ACCLAIM-2 RATIONALE mike thachad ung cancer Nasdog:GNEK 25
Slide 26: Scaled-Up Clinical Grade Manufacturing
SCALED-UP CLINICAL GRADE MANUFACTURING MILESTONE POSITIONS COMPANY FOR SUCCESS IN LUNG CANCER THERAPEUTICS MARKET and significantly improved economies of scale. + Successful completion of technology transfer and scale-up of REQORSA + GMP production provides supply for two upcoming Acclaim clinical t
Slide 27: Diabetes Program
DIABETES PROGRAM
Slide 28: Diabetic Patients in Need of Advanced Therapy
DIABETIC PATIENTS IN NEED OF ADVANCED THERAPY GPX-002 MAY ELIMINATE NEED FOR INSULIN IN DIABETIC PATIENTS ‘Type 1 and Type 2 diabetes affect approximately 34 million people in the U.S', or 10 percent of the U.S. population. May replace daily burden of blood glucose i monitoring and insulin replaceme
Slide 29: GPX-002 Replenishes Levels of Insulin
3 GPX-002 REPLENISHES LEVELS OF INSULIN REPROGRAMS AND RESTORES CELL FUNCTION Novel infusion process uses an endoscope and an ‘AAV vector to deliver the Pax and MafA genes to the pancreas. Transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are disti
Slide 30: Key Milestones Through 2021 & Beyond
KEY MILESTONES THROUGH 2021 & BEYOND COMPLETED ANTICIPATED ‘Successful completion and ‘scale-up of REQORSA, Initiated site recruitment for both Acclaim clinical trials Reported preclinical data for REQORSA in Dose the first patient in each of the Acclaim clinical wials ‘Announce interim data from th
Slide 31: Some Targeted Therapy Company Valuations
SOME TARGETED THERAPY COMPANY VALUATIONS == Sa tovace Blotherapectes MatiTerapmies TK Nasdog mamaceniats SOK Nasdog Tomas Terk Nase Genprox ine. GNP asdog Genprex —Upsneaorios202t envious Ph v2 ‘Melanoma, Head ana Neck erat Wet. hone tymphocyte Leuker Unive Nes SCL Colorectal Renal yprya4s, siravati
Slide 32: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT. RODNEY VARNER, JD Chairman, President & Chief Executive Officer + 30+ years of expertise in corporate law, induding ‘corporate governance, in biotech industy + Former owner of securities broker dealer frm MICHAEL REDMAN Executive VP & Chief Operating Officer + 30+ y
Slide 33: Meet Our Team
MEET OUR TEAM COMPANY MANAGEMENT. THOMAS GALLAGHER, Senior Vice President, Intellectual Property and Licensing 20 years of expertise in biotech law, business lopment, heensing + Senne Pcsaareng rey SHANNON INMAN, Vice President of Global Clinical Operations + 20+ years of clinical operations experti
Slide 34: Scientific Advisory Board
MEET OUR TEAM SCIENTIFIC ADVISORY BOARD JACK A. ROTH Director, WM. Keck Center for Innovative Cancer Therapies TONY S. K. MOK MD, FRCP(C), FHKCP, FHKAM + Professor and Chair of Clinical Oncology, the University of Hong Kong: Co-founder of the Lung ancer Research Grou + Chairman, Department of Clinic
Slide 35: Clinical Advisory Board
MEET OUR TEAM CLINICAL ADVISORY BOARD MICHAEL MORSE COL. GEORGE PEOPLES MD, MHS, FACP > fda + Professor of Medicine, Division of Medical Oncology 4 + Chief Executive Officer of Cancer Insight, LLC, a RO + Reseach expertise in targeted therapies and + Professor of Surgery at Uniformed Se Imanctherpie
Slide 36: Board of Directors
MEET OUR TEAM BOARD OF DIRECTORS RODNEY VARNER, JD Chairman of the Board + 30+ years of expertise in corporate law, including ‘corporate governance, n biotech industry + Former owner of securities broker dealer frm JOSE A. MORENO TOSCANO Board Director Chief Executive Officer, LFB USA nc 20+ years o
Slide 37: In a Future of Transformational Patient Care
IN A FUTURE OF TRANSFORMATIONAL PATIENT CARE 21ST CENTURY GENE THERAPIES LARGE MARKETS AND UNMET NEED COMBINATION TRIALS WITH TOP SELLING DRUGS. FAST TRACK DESIGNATION EXPLORING NEW INDICATIONS AND PARTNERSHIPS
Slide 38: Genprex
oO Genprex’ NASDAQ: GNPX (877) 774- GNPX | investors@genprex.com Naséaa:GNPX
Slide 39: Appendix
Slide 40: Two New Combination Clinical Trials
TWO NEW COMBINATION CLINICAL TRIALS Poth MDLONZUMAD) tascen sty =x Genprex Nasdaq: GNPK
Slide 41: Effects of Genetic Alterations in Suppressor Genes
EFFECTS OF GENETIC ALTERATIONS IN SUPPRESSOR GENES i LC are located i ich no targeted agents have been developed. + Regulation of Malignant Tumor Growth + Insensitivity to Growth- inhibitory Signals + Evasions of Programmed Cell Death (Apoptosis) + Limitless Replicative Potential + Induced Angiogene
Slide 42: Why Systemic Gene Therapy?
WHY SYSTEMIC GENE THERAPY? Lipid nanoparticles have been shown to encapsulate plasmid DNA, which allows the delivery of gene therapeutic agents intravenously to distant metastases Lipid nanoparticles with TUSC2 have up to a 33-fold affinity for cancer cells compared to healthy cells No need to attac
Slide 43: Why TUSC2?
WHY TUSC2? ‘© 80% of all lung cancer cells lack the TUSC2 tumor suppressor gene ‘+ Loss or reduction of TUSC2 expression is associated with significantly worse overall survival vels of TUSC2 compared with normal bronchial epithelia Nasdaq: GNOK
Slide 44: Viral vs. Non-Viral Vectors
VIRAL VS. NON-VIRAL VECTORS i ie ess endency General tse pect of gets Reported cases of death and causing leukemia Lipoplex Non-Viral Vectors + High level of transfection efficiency Highest stability No viral particles that can be immunogenic Lowest toxicity Super cancer cells, the DNA Genprex Naséa
Slide 45: Other Potential Cancer Indications
OTHER POTENTIAL CANCER INDICATIONS The region of the TUSC2 tumor suppressor gene is associated with chromosome 3p. In addition to NSCLC, other potential indications include: Thyroid Renal Breast Head & Neck Mesothelioma Ovary ancer 942009, doar 6/1476 4508 8 91 ‘eH Huon Hon 1, Ren WR, Yong Naséaa:GN
Slide 46: REQORSA + Tagrisso Reduce Tumor Growth
REQORSA + TAGRISSO REDUCE TUMOR GROWTH EFFECT OF TAGRISSO (OSIMERTINIB) + TUSC2 ON A549-LUC METASTASIS ON NSG MICE TEREPES (iment is the generic form of Tagriso Naséoa:GNex 45
Slide 47: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model
>) Genprex EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL Carbo+Pembro Effect of Carbo+Pembro+TUSC2 on TusC2 Carbo+Pembro-+TUSC2 A549 tang me met on Hu-NSG_ °% of change (wk2 vs wk5) ior etal embrolzumab i the generc name for Keyruda. Nasdog:GNEK 47
Slide 48: Effect of REQORSA + Carbo + Keytruda on Humanized A549 Lung Metastasis Model
EFFECT OF REQORSA + CARBO + KEYTRUDA ON HUMANIZED A549 LUNG METASTASIS MODEL ascoe| Bir om O10" |—- Carbo+Pembro: Pa TS | & oetge | CattorPembro+Tuscz Beer s) é a Su ’ fi sae Effect of CarbotPembro+TUSC2 on A549 lung met on Hu-NSG 610°] -— No treatment Pembrolizumab i the generic nome for Keytruda,